Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
JCI accreditation is recognized globally
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Pflow is a revolutionary, disposable, and portable home based urine flow measurement test
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divestment is part of BASF’s strategic portfolio optimization
Exploring new opportunities within the fast-growing market of microfluidics
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Subscribe To Our Newsletter & Stay Updated